A 2-point improvement in pain based on a numeric rating scale may indicate that patients are responding to treatment for pyoderma gangrenosum. To help determine whether a patient with pyoderma ...

Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...

Nepal: Pyoderma gangrenosum (PG) can occur without associated systemic disease and may resemble infectious or vascular ulcers ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

The misdiagnosis of pyoderma gangrenosum can have serious consequences. Cutaneous ulcerations in patients with suspected pyoderma gangrenosum often prove, on further workup, to have a different cause.

DEAR DR. ROACH: I am a 74-year-old woman in good health. I was diagnosed with pyoderma gangrenosum on my left leg. I was in a lot of pain. Can you tell me the cause of this rare disease? Also, is ...

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE)-- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...